Theravance Biopharma logo

Theravance BiopharmaNASDAQ: TBPH

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 May 2014

Next earnings report:

26 February 2025

Last dividends:

N/A

Next dividends:

N/A
$469.61 M
-51%vs. 3y high
65%vs. sector
-vs. 3y high
-vs. sector
-3%vs. 3y high
66%vs. sector
-57%vs. 3y high
71%vs. sector

Price

after hours | Fri, 15 Nov 2024 21:31:52 GMT
$9.55-$0.02(-0.21%)

Dividend

No data over the past 3 years
$16.87 M$27.32 M
$16.87 M-$12.70 M

Analysts recommendations

Institutional Ownership

TBPH Latest News

Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
zacks.com13 November 2024 Sentiment: POSITIVE

TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.

Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates
zacks.com12 November 2024 Sentiment: POSITIVE

Theravance Biopharma (TBPH) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.01 per share a year ago.

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value
prnewswire.com12 November 2024 Sentiment: POSITIVE

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 20241 CYPRESS enrollment in-line with expectations, with timelines on track TRELEGY net sales increased 17%, to $789 million, as reported by GSK: Q4 sales of at least ~$260 million needed to earn $25 million milestone2 Q4 sales of  at least ~$610 million needed to earn $50 million milestone2 Board of Directors announces initiatives to unlock shareholder value and enhance corporate governance DUBLIN , Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2024 and announced the formation of a Strategic Review Committee to assess alternatives to unlock shareholder value. Reflecting on the quarter's operational performance, Rick Winningham, Theravance Biopharma CEO commented, "Through our collaboration with Viatris, we achieved a strong quarter for YUPELRI demand and made progress on recent mix-related pricing headwinds, therein driving quarterly net sales to an all-time high.

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024
prnewswire.com24 October 2024 Sentiment: NEUTRAL

DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2024 financial results and provide a business update after market close on Tuesday, November 12, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day.

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease
prnewswire.com18 October 2024 Sentiment: POSITIVE

DUBLIN , Oct. 18, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the publication of a sub-study of the pivotal 12-week, randomized, registrational revefenacin Phase 3 trials (Trials 0126 [NCT02459080] and 0127 [NCT02512510]) for YUPELRI, the first and only FDA approved once-daily nebulized long-acting muscarinic antagonist (LAMA), evaluating the area under the curve (AUC) lung function effects in moderate-to-very-severe chronic obstructive pulmonary disease (COPD) patients.  These data and analyses, published in the International Journal of Chronic Obstructive Pulmonary Disease, reinforce that YUPELRI provides consistent and durable improvements in lung function, as compared with placebo, over a full 24-hours.

Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
zacks.com04 September 2024 Sentiment: POSITIVE

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Theravance Biopharma to Participate in an Upcoming Investor Conference
prnewswire.com27 August 2024 Sentiment: POSITIVE

DUBLIN , Aug. 27, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City on Tuesday, September 10 at 10:00 am ET (7:00 am PT/3:00 pm IST) and will be hosting in-person meetings with the investment community at the conference.

Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
zacks.com06 August 2024 Sentiment: NEUTRAL

Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
zacks.com05 August 2024 Sentiment: NEGATIVE

Theravance Biopharma (TBPH) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.13 per share a year ago.

Theravance Biopharma to Participate in an Upcoming Investor Conference
prnewswire.com25 July 2024 Sentiment: POSITIVE

DUBLIN , July 25, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 6 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference.

  • 1(current)
  • 2

What type of business is Theravance Biopharma?

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

What sector is Theravance Biopharma in?

Theravance Biopharma is in the Healthcare sector

What industry is Theravance Biopharma in?

Theravance Biopharma is in the Biotechnology industry

What country is Theravance Biopharma from?

Theravance Biopharma is headquartered in United States

When did Theravance Biopharma go public?

Theravance Biopharma initial public offering (IPO) was on 16 May 2014

What is Theravance Biopharma website?

https://www.theravance.com

Is Theravance Biopharma in the S&P 500?

No, Theravance Biopharma is not included in the S&P 500 index

Is Theravance Biopharma in the NASDAQ 100?

No, Theravance Biopharma is not included in the NASDAQ 100 index

Is Theravance Biopharma in the Dow Jones?

No, Theravance Biopharma is not included in the Dow Jones index

When was Theravance Biopharma the previous earnings report?

No data

When does Theravance Biopharma earnings report?

The next expected earnings date for Theravance Biopharma is 26 February 2025